Aspirin 75mg Gastro-Resistant Tablets

Concepts (37)

• +Bleeding riskContraindicated

  … tors (e.g. certain asthma patients who may suffer an attack or faint and certain patients who may suffer from bronchospasm, rhinitis and urticaria), or to any of the excipients (see section 6.1). • Active, or history of recurrent peptic ulcer and/or gastric/intestinal haemorrhage, or other kinds of bleeding such as cerebrovascular haemorrhages. • Haemorrhagic diathesis; coagulation disorders such as haemophilia and thrombocytopenia. • Patients who are suffering from gout. • Severe hepatic impairment. • Severe renal impairment. • …

  Source SmPC ↗
• +Stomach and gutContraindicated

  … tors (e.g. certain asthma patients who may suffer an attack or faint and certain patients who may suffer from bronchospasm, rhinitis and urticaria), or to any of the excipients (see section 6.1). • Active, or history of recurrent peptic ulcer and/or gastric/intestinal haemorrhage, or other kinds of bleeding such as cerebrovascular haemorrhages. • Haemorrhagic diathesis; coagulation disorders such as haemophilia and thrombocytopenia. • Patients who are suffering from gout. • Severe hepatic impairment. • Severe renal impairment. • …

  Source SmPC ↗
• +Blood disordersContraindicated

  … o any of the excipients (see section 6.1). • Active, or history of recurrent peptic ulcer and/or gastric/intestinal haemorrhage, or other kinds of bleeding such as cerebrovascular haemorrhages. • Haemorrhagic diathesis; coagulation disorders such as haemophilia and thrombocytopenia. • Patients who are suffering from gout. • Severe hepatic impairment. • Severe renal impairment. • Doses >100 mg/day during the third trimester of pregnancy (see section 4.6); • Methotrexa …

  Source SmPC ↗
• +Liver conditionsContraindicated

  … ther kinds of bleeding such as cerebrovascular haemorrhages. • Haemorrhagic diathesis; coagulation disorders such as haemophilia and thrombocytopenia. • Patients who are suffering from gout. • Severe hepatic impairment. • Severe renal impairment. • Doses >100 mg/day during the third trimester of pregnancy (see section 4.6); • Methotrexate used at doses >15mg/week (see section 4.5).

  Source SmPC ↗
• +Allergy to the medicineContraindicated

  • Hypersensitivity to salicylic acid compounds or prostaglandin synthetase inhibitors (e.g. certain asthma patients who may suffer an attack or faint and certain patients who may suffer from bronchospasm, rhinitis and urticaria), or to any of the excipients (see section 6.1). • Active, or history of recurrent peptic ulcer and/or gastric/intestinal haemorrhage, or other kinds of bleeding such as cerebrovascular haemorrhages. • Haemorrhagic diathesis; coagulation disord …

  Source SmPC ↗
• +PregnancyContraindicated

  … • Haemorrhagic diathesis; coagulation disorders such as haemophilia and thrombocytopenia. • Patients who are suffering from gout. • Severe hepatic impairment. • Severe renal impairment. • Doses >100 mg/day during the third trimester of pregnancy (see section 4.6); • Methotrexate used at doses >15mg/week (see section 4.5).

  Source SmPC ↗
• +Kidney conditionsContraindicated

  … cerebrovascular haemorrhages. • Haemorrhagic diathesis; coagulation disorders such as haemophilia and thrombocytopenia. • Patients who are suffering from gout. • Severe hepatic impairment. • Severe renal impairment. • Doses >100 mg/day during the third trimester of pregnancy (see section 4.6); • Methotrexate used at doses >15mg/week (see section 4.5).

  Source SmPC ↗
• +Breathing conditionsContraindicated

  • Hypersensitivity to salicylic acid compounds or prostaglandin synthetase inhibitors (e.g. certain asthma patients who may suffer an attack or faint and certain patients who may suffer from bronchospasm, rhinitis and urticaria), or to any of the excipients (see section 6.1). • Active, or history of recurrent peptic ulcer and/or gastric/intestinal haemorrhage, or other kinds of bleeding such as cerebrovascular haemorrhages. • Haemorrhagic diathesis; coagulation disord …

  Source SmPC ↗
• +UnclassifiedContraindicated

  … nd/or gastric/intestinal haemorrhage, or other kinds of bleeding such as cerebrovascular haemorrhages. • Haemorrhagic diathesis; coagulation disorders such as haemophilia and thrombocytopenia. • Patients who are suffering from gout. • Severe hepatic impairment. • Severe renal impairment. • Doses >100 mg/day during the third trimester of pregnancy (see section 4.6); • Methotrexate used at doses >15mg/week (see section 4. …

  Source SmPC ↗
• +Taken with other medicinesWarning

  … or use in adolescents/children under 16 years unless the expected benefits outweigh the risks. Acetylsalicylic acid may be a contributory factor in the causation of Reye's Syndrome in some children. There is an increased risk of haemorrhage particularly during or after operative procedures (even in cases of minor procedures, e.g. tooth extraction). Use with caution before surgery, including tooth extraction. Temporary discontinuation of treatment may be necessary. Aspirin is not recommended during menorrhagia where it may increase menstrual bleeding. Aspirin 75 mg tablets is to be used with caution in cases of hypertension and when patients have a past histo …

  Source SmPC ↗
• +Older peopleWarning

  … sociation with the use of acetylsalicylic acid (see section 4.8). Aspirin tablets should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity. Elderly patients are particularly susceptible to the adverse effects of NSAIDs, including acetylsalicylic acid especially gastrointestinal bleeding and perforation which may be fatal (see section 4.2). Where prolonged therapy is required, patients should be reviewed regularly. Concomitant treatment with Aspirin and other drugs that alter haemostasis (i.e. anticoagulants such as warfarin, thrombolytic and antiplatelet agents, anti-inflammatory drugs and selective serotonin …

  Source SmPC ↗
• +Enzyme deficiencyWarning

  … d insulins may be potentiated with Aspirin 75mg tablets taken at over dosage (see section 4.5). Aspirin should be avoided in late pregnancy and generally during breast feeding (see section 4.6). Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

  Source SmPC ↗
• +Intolerance to an ingredientWarning

  … d insulins may be potentiated with Aspirin 75mg tablets taken at over dosage (see section 4.5). Aspirin should be avoided in late pregnancy and generally during breast feeding (see section 4.6). Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

  Source SmPC ↗
• +LactoseWarning

  … d insulins may be potentiated with Aspirin 75mg tablets taken at over dosage (see section 4.5). Aspirin should be avoided in late pregnancy and generally during breast feeding (see section 4.6). Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

  Source SmPC ↗
• +BlockageWarning

  … sociation with the use of acetylsalicylic acid (see section 4.8). Aspirin tablets should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity. Elderly patients are particularly susceptible to the adverse effects of NSAIDs, including acetylsalicylic acid especially gastrointestinal bleeding and perforation which may be fatal (see section 4.2). Where prolonged therapy is required, patients should be reviewed regularly. Concomitant treatment with Aspirin and other drugs that alter haemostasis (i.e. anticoagulants such as warfarin, thrombolytic and antiplatelet agents, anti-inflammatory drugs and selective serotonin …

  Source SmPC ↗
• +ChildrenWarning

  Aspirin 75 mg tablets is not suitable for use as an anti-inflammatory/ analgesic/ antipyretic. Recommended for use in adults and adolescents from 16 years of age. This medicinal product is not recommended for use in adolescents/children under 16 years unless the expected benefits outweigh the risks. Acetylsalicylic acid may be a contributory factor in the causation of Reye's Syndrome in some children. There is an increased risk of haemorrhage particularly during or after operative procedures (even in cases of minor procedures, e.g. tooth extraction). Use with caution before surgery, including too …

  Source SmPC ↗
• +Serotonin effectsWarning

  … including acetylsalicylic acid especially gastrointestinal bleeding and perforation which may be fatal (see section 4.2). Where prolonged therapy is required, patients should be reviewed regularly. Concomitant treatment with Aspirin and other drugs that alter haemostasis (i.e. anticoagulants such as warfarin, thrombolytic and antiplatelet agents, anti-inflammatory drugs and selective serotonin reuptake inhibitors) is not recommended, unless strictly indicated, because they may enhance the risk of haemorrhage (see section 4.5). If the combination cannot be avoided, close observation for signs of bleeding is recommended. Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration, such as oral corticosteroids, selective serotonin-reuptake inhibitors and deferas …

  Source SmPC ↗
• +Gap needed after another medicineWarning

  … or use in adolescents/children under 16 years unless the expected benefits outweigh the risks. Acetylsalicylic acid may be a contributory factor in the causation of Reye's Syndrome in some children. There is an increased risk of haemorrhage particularly during or after operative procedures (even in cases of minor procedures, e.g. tooth extraction). Use with caution before surgery, including tooth extraction. Temporary discontinuation of treatment may be necessary. Aspirin is not recommended during menorrhagia where it may increase menstrual bleeding. Aspirin 75 mg tablets is to be used with caution in cases of hypertension and when patients have a past histo …

  Source SmPC ↗
• +AlcoholInteraction

  … ead to decreased total phenytoin levels in plasma, but increased free phenytoin fraction. The unbound concentration, and thereby the therapeutic effect, does not appear to be significantly altered. Alcohol: Concomitant administration of alcohol and acetylsalicylic acid increases the risk of gastrointestinal bleeding. Antacids will reduce the effect of aspirin. Principle incompatibilities are iron sal …

  Source SmPC ↗
• +Acid build-up in the bloodInteraction

  … tion via decreased renal prostaglandin synthesis. Hydrating the patient and monitoring renal function at the start of the treatment is recommended. Carbonic anhydrase inhibitors (acetazolamide): May result in severe acidosis and increased central nervous system toxicity. Systemic corticosteroids: The risk of gastrointestinal bleeding and ulceration is increased when acetylsalicylic acid and corticosteroids are co-administered (see section 4.4). Methotrexate (u …

  Source SmPC ↗
• +BreastfeedingPregnancy

  … doses higher than 100 mg/day is contraindicated during the third trimester of pregnancy (see section 4.3). Doses up to and including 100 mg/day may only be used under strict obstetric monitoring. Breast-feeding Low quantities of salicylates and of their metabolites are excreted in breast milk. Since adverse effects for the infant have not been reported up to now, short-term use of the recommended dose do …

  Source SmPC ↗
• +Heart conditionsPregnancy

  … regarding the use of doses above 100 mg/day up to 500 mg/day. Therefore, the recommendations below for doses of 500 mg/day and above apply also for this dose range. Doses of 500 mg/day and above: Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformation was increased from less than 1%, up to approximately 1.5 %. The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre and post-implantation loss and embryo-foetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period. During the first and second trimester of pregnancy, acetylsalicylic acid should not be given unless clearly necessary. If acetylsalicylic acid is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible. From the 20th week of pregnancy onward, acetylsalicylic acid use may cause oligohydramnios resulting from foetal renal dysfunction. This may occur shortly after treatment initiation and is usually r …

  Source SmPC ↗
• +Angioedema (deep swelling)—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.

• +Azo colourants—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.

• +Benzyl alcohol—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.

• +Dehydration—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.

• +Salt and mineral balance—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.

• +Fertility—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.

• +Low blood pressure—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.

• +Vaccination—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.

• +Infection—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.

• +Sodium and potassium content—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.

• +Peanut—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.

• +Propylene glycol—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.

• +Soya—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.

• +Blood clots—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.

• +Thyroid—Not in scanned sections

  Not found in the sections read for this label. Not the same as the label being silent.